Hasan Ashfaq, Mukherjee Priyanka, Chhowala Sushmeeta, Lopez Meena, Chhajed Prashant N
Professor, Department of Pulmonary Medicine, Deccan College of Medical Sciences, Hyderabad, Telangana, India.
Cipla Ltd., Mumbai, Maharashtra, India.
Lung India. 2021 Jul-Aug;38(4):350-358. doi: 10.4103/lungindia.lungindia_394_20.
Asthma and chronic obstructive pulmonary disease (COPD) are common chronic respiratory diseases characterized by an inflammatory process that extends from the central to peripheral airways. Conventional pressurized metered-dose inhalers and most dry-powder inhalers emit drug particles too large to target the small airways effectively. Advancements in drug formulation have given rise to a new generation of inhalers that can generate aerosols with extrafine drug particles that leads to more effective aerosol penetration into the lung periphery. An extrafine formulation of inhaled beclomethasone/formoterol (BDP-FF) with enhanced lung deposition is now available. This document reviews the various real-world and controlled studies that have evaluated the efficacy of extrafine BDP-FF in asthma and COPD.
哮喘和慢性阻塞性肺疾病（COPD）是常见的慢性呼吸道疾病，其特征是炎症过程从中央气道延伸至外周气道。传统的压力定量吸入器和大多数干粉吸入器喷出的药物颗粒太大，无法有效靶向小气道。药物制剂的进步催生了新一代吸入器，这些吸入器能够产生带有超细微药物颗粒的气雾剂，从而使气雾剂更有效地渗透到肺外周。现在有一种吸入用倍氯米松/福莫特罗（BDP-FF）的超细微制剂，其肺部沉积效果得到了增强。本文献回顾了各种评估超细微BDP-FF在哮喘和COPD中疗效的真实世界研究和对照研究。
